Co-Diagnostics, Inc. — Form 8-K
Filed July 27, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Co-Diagnostics amended its October 20, 2025 Equity Distribution Agreement with Maxim Group LLC effective July 27, 2026. The amendment removes the prior $10 million cap on aggregate offering price and allows up to $7,901,383 in additional shares to be registered and sold under a new Form S-3 (File 333-295803, effective May 15, 2026). The agreement remains an at-the-market offering with Maxim as exclusive sales agent; either party may terminate with 10 days' notice.
Why this rating
This is 79% of company's $10M market cap—a material financing expansion. Removes prior cap, enabling substantial capital raise relative to current size, but execution risk remains high.
See more from July 27, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.